Treatment deescalation for older women with favorable breast cancers: patient values and shared decision making
- PMID: 40232739
- PMCID: PMC12145919
- DOI: 10.1093/jnci/djaf001
Treatment deescalation for older women with favorable breast cancers: patient values and shared decision making
Conflict of interest statement
Deborah R. Smith has no disclosures. Silvia C. Formenti reports grants from the National Cancer Institute (NCI) U54 CA274291, Department of Defense (DoD) BC180595/W81XWH-19-1-0142 and BC201085P3 W81XHW21-2-0034, Congressionally Directed Medical Research Programs, Breast Cancer Research Foundation (BCRF) -24-053, Merck, Arcus, and Celldex. Also, she reports, Bristol Myers Squibb and Varian, consultant fees from AstraZeneca, Regeneron, Merck, Genentech Roche, EMD Serono, Viewray, Varian, Boehringer Ingelheim, Nanobiotix, Telix, and EMBiosys.
Comment on
-
Omission of postoperative radiotherapy after breast-conserving surgery in low-risk breast cancer.J Natl Cancer Inst. 2025 Jun 1;117(6):1125-1133. doi: 10.1093/jnci/djae315. J Natl Cancer Inst. 2025. PMID: 39656805 Free PMC article.
References
-
- Darby S, McGale P, Correa C, et al.; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707-1716. 10.1016/S0140-6736(11)61629-2. - DOI - PMC - PubMed
-
- Grantzau T, Overgaard J.. Risk of second non-breast cancer among patients treated with and without postoperative radiotherapy for primary breast cancer: a systematic review and meta-analysis of population-based studies including 522,739 patients. Radiother Oncol. 2016;121:402-413. 10.1016/j.radonc.2016.08.017 - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
